- Home
- TCRT vs ACON Comparison
TCRT vs ACON Comparison
Compare TCRT & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- ACON
- Stock Information
- Founded
- TCRT 1998
- ACON 2008
- Country
- TCRT United States
- ACON United States
- Employees
- TCRT N/A
- ACON N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- TCRT Health Care
- ACON Technology
- Exchange
- TCRT Nasdaq
- ACON Nasdaq
- Market Cap
- TCRT 3.8M
- ACON 4.2M
- IPO Year
- TCRT N/A
- ACON 2022
- Fundamental
- Price
- TCRT $5.02
- ACON $7.28
- Analyst Decision
- TCRT
- ACON Buy
- Analyst Count
- TCRT 0
- ACON 2
- Target Price
- TCRT N/A
- ACON $481.00
- AVG Volume (30 Days)
- TCRT 45.5K
- ACON 15.5K
- Earning Date
- TCRT 08-13-2025
- ACON 08-13-2025
- Dividend Yield
- TCRT N/A
- ACON N/A
- EPS Growth
- TCRT N/A
- ACON N/A
- EPS
- TCRT N/A
- ACON N/A
- Revenue
- TCRT $11,000.00
- ACON $54,601.00
- Revenue This Year
- TCRT $5,680,500.00
- ACON $212.31
- Revenue Next Year
- TCRT N/A
- ACON $92.86
- P/E Ratio
- TCRT N/A
- ACON N/A
- Revenue Growth
- TCRT 83.33
- ACON N/A
- 52 Week Low
- TCRT $1.31
- ACON $6.20
- 52 Week High
- TCRT $7.40
- ACON $3,499.51
- Technical
- Relative Strength Index (RSI)
- TCRT 76.09
- ACON 42.96
- Support Level
- TCRT $3.00
- ACON $6.79
- Resistance Level
- TCRT $4.92
- ACON $7.29
- Average True Range (ATR)
- TCRT 0.63
- ACON 0.37
- MACD
- TCRT 0.18
- ACON 0.31
- Stochastic Oscillator
- TCRT 98.55
- ACON 45.79
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.